Printer Friendly

ARROW INTERNATIONAL, INC. HOLDS SHAREHOLDER MEETING

 READING, Pa., Jan. 21 /PRNewswire/ -- During Arrow International's (NASDAQ-NMS: ARRO) annual meeting of shareholders yesterday in Reading, Marlin Miller, president and chief executive officer, told shareholders that net income growth should exceed sales growth for the year due to expanding gross profit margins.
 Based on the current outlook, Miller continues to feel that analysts' estimates of earnings per share of $1.05 to $1.10 for the year are reasonable.
 While the company remains confident in its long range growth target of 20-25 percent per year, second quarter revenue growth over the unusually strong 1992 FY second quarter should be in the range of 10 percent. Revenue growth is being held back this year by Food & Drug Administration delays in new product approvals and by lower than expected distributor sales. Important new product approvals are targeted for early in the third quarter which, when coupled with increased distributor sales support, should accelerate revenue growth in the second half of the fiscal year. Percentage revenue growth for the 1993 fiscal year will most likely be in the mid-teens.
 Gross profit margins are being favorably impacted by increasing acceptance of the company's proprietary ARROWgard(TM) antiseptic surface treatment for catheter products and several manufacturing efficiencies now coming on line. Miller's remarks to shareholders also reviewed the company's basic philosophy and direction and covered in some depth new products important to Arrow's future growth, as follows:
 -- ARROWgard(TM) antiseptic surface treated catheters are gaining increased acceptance and are a major contributor to improving gross profit margins.
 -- QuickFlash(TM) radial artery catheters, introduced in late October 1992, are now in volume production and based on early physician reactions should significantly increase Arrow's penetration of the radial artery catheter market.
 -- A new arterial access needle, E.V.A.N. (Ergonomic Vascular Access Needle), received positive response at recent medical meetings and will go into worldwide distribution as soon as FDA marketing approval is received. Approval is targeted for February or March 1993. This new access needle makes possible the verification of arterial placement through observation of pulsatile pressure while at the same time containing blood flow and providing for the introduction of a guide wire through a hemostasis valve mounted on the needle handle. The hemostasis valve greatly reduces the exposure of healthcare professionals to blood during the arterial access procedure. This product addresses an arterial needle market which industry reports estimate at 1.3 million units annually in the U.S.A. with an equal or greater market internationally. Unit pricing will be in the $8 range.
 -- The new Super ArrowFlex(TM) kink resistant vascular access sheath designed to facilitate vascular intervention in a wide range of procedures is also awaiting FDA marketing approval now targeted for March 1993. This new sheath is constructed with coiled wire encapsulated in the sheath's plastic wall that provides kink resistance over a radius as small as 1/4-inch. Sheath kinking is a major problem in the exchange of catheters during interventional procedures. Physician reaction to this product has been enthusiastic. With the present U.S. sheath market estimated by industry reports to be $50 million, it is anticipated that the Super ArrowFlex(TM) sheath will become a major Arrow product. U.S. patent No. 5,190,376 for the sheath product was issued on Jan. 19, 1993, to the inventor, Robert E. Fischell. Arrow is the exclusive licensee of this patented product.
 -- Arrow's PAC (Pullback Atherectomy Catheter) is proceeding through human clinical trials in leg vessels. Of 200 planned cases, nearly half are completed, with a current expectation that all cases will be finished and FDA approval for commercial sale applied for in the fall of 1993. FDA marketing approval would be anticipated sometime in 1994. Approval to begin human coronary artery trials is contingent on further animal tests requested by FDA. Submission of this data to the FDA is targeted for May/June 1993 with permission to begin tests targeted for the summer of 1993.
 Arrow International, Inc. develops, manufacturers and markets a broad range of clinically advanced, disposable catheters and related products. The company's products are used primaricians. These critical care products are used principally for central vascular access for administration of fluids, drugs and blood products, patient monitoring and diagnostic purposes, as well as for pain management. The company's shares are traded in the Over-the-Counter market on the NASDAQ National Market System under the symbol ARRO.
 /delval/
 -0- 1/21/93
 /CONTACT: Marlin Miller Jr., 215-478-3114, or John H. Broadbent, 215-478-3116, both of Arrow International/
 (ARRO)


CO: Arrow International, Inc. ST: Pennsylvania IN: MTC SU: ERP

LJ -- PH006 -- 7259 01/21/93 09:17 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 21, 1993
Words:771
Previous Article:ROLLINS ENVIRONMENTAL SERVICES, INC. REPORTS RESULTS FOR FIRST QUARTER
Next Article:PHILADELPHIA FED RELEASES JANUARY BUSINESS OUTLOOK SURVEY
Topics:


Related Articles
ARROW INTERNATIONAL REPORTS STRONG GROWTH IN FIRST QUARTER SALES AND EARNINGS
ARROW INTERNATIONAL REPORTS 21.5% INCREASE IN FIRST QUARTER NET INCOME
ARROW INTERNATIONAL, INC. SHAREHOLDER MEETING HELD JANUARY 19, 1994
ARROW INTERNATIONAL REPORTS 18.5% INCREASE IN FIRST QUARTER NET INCOME
ARROW INTERNATIONAL, INC. REPORTS 14.9% INCREASE IN FIRST QUARTER NET INCOME
Arrow International Announces Dividend For Third Fiscal Quarter
Arrow International Files and Mails Definitive Proxy Materials.
Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors.
Proxy Governance Joins ISS, Glass Lewis and Egan Jones in Recommending Arrow International Shareholders Vote to Approve the $45.50 Per Share Merger...
Arrow International Announces Annual Meeting Voting Results.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters